XTX Topco’s Alaunos Therapeutics TCRT Stock Holding History

XTX Topco’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,174	Closed	-$29.1K	–	4695
2026 Q1	$29.1K	Buy	+10,174	New	+$30.4K	﹤0.01%	3464
2022 Q4	–	Sell	-158	Closed	-$41K	–	1499
2022 Q3	$41K	Buy	+158	New	+$45.9K	0.01%	1039
2022 Q1	–	Sell	-294	Closed	-$48K	–	946
2021 Q4	$48K	Buy	+294	New	+$64.6K	0.03%	570
2021 Q3	–	Sell	-320	Closed	-$127K	–	1051
2021 Q2	$127K	Buy	320 +189	+144%	+$88.2K	0.04%	629
2021 Q1	$71K	Buy	+131	New	+$81.6K	0.03%	596

Other funds holding TCRT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

XTX Topco's TCRT Position: Q2 2026 in Review

XTX Topco sold out of Alaunos Therapeutics (TCRT) in Q2 2026, closing a stake of 10,174 shares — an estimated $29.1K sold.

XTX Topco first reported a position in TCRT in Q1 2021 and held it in 5 quarters. The position peaked at $127K in Q2 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

XTX Topco reported no remaining Alaunos Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 10,174 Alaunos Therapeutics shares in Q2 2026, an estimated $29.1K.
XTX Topco first reported a position in Alaunos Therapeutics in Q1 2021 and held it in 5 quarters.
XTX Topco's Alaunos Therapeutics position peaked at $127K in Q2 2021.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.